Indeed, triple-negative breast cancer had a poor 5-year survival (33.19%) compared to luminal A (54.89%), luminal B Her2- (53.17%), luminal B Her2+ (68.89%) and Her2 (48.95%) (p = 0.0001) (Fig. 4B). Here, ERBB2 is linked to triple-negative breast carcinoma.